Cargando…
Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure
Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent manifestation of PH but lacks any approved treatment. Activin receptor type IIA-Fc fusion protein (ActRIIA-Fc) was found previously to be efficacious in experimental and human pulmonary arterial hypertension (PAH). Here w...
Autores principales: | Joshi, Sachindra R., Atabay, Elif Karaca, Liu, Jun, Ding, Yan, Briscoe, Steven D., Alexander, Mark J., Andre, Patrick, Kumar, Ravindra, Li, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996114/ https://www.ncbi.nlm.nih.gov/pubmed/36910526 http://dx.doi.org/10.3389/fcvm.2023.1064290 |
Ejemplares similares
-
Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension
por: Joshi, Sachindra R., et al.
Publicado: (2022) -
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023) -
Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling
por: Andre, Patrick, et al.
Publicado: (2022) -
Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014) -
Sotatercept for the treatment of pulmonary arterial hypertension: a meta-analysis of randomized controlled trials
por: Jaiswal, Vikash, et al.
Publicado: (2023)